(ECOR) electroCore, Inc. Business Model Canvas Research

electroCore, Inc. depends on third-party suppliers for device parts, assembly, and packaging for its FDA-cleared portable neuromodulation device, gammaCore. These partners matter because the product must meet strict quality and regulatory controls while keeping supply steady across the U.S. and international markets.

That setup lowers in-house manufacturing load, but it also makes continuity, lead times, and supplier quality central to revenue support and patient access.

• Third parties source key device inputs
• Assembly and packaging are outsourced
• Quality control supports regulatory compliance
• Supply continuity protects market access

Government and research-group partnerships help electroCore, Inc. build clinical evidence for nVNS, support guideline awareness, and speed adoption in headache care settings. Public-sector and healthcare-system ties also help validate use across real-world sites, which matters for institutional buying and payer confidence.

• Supports evidence generation
• Raises guideline awareness
• Builds institutional trust

payer access and reimbursement is a core activity for electroCore, Inc. because prescription devices only convert to use when coverage is in place. The Company runs reimbursement support, benefit verification, and payer outreach to cut friction at the point of access and improve prescription-to-use conversion.

• coverage drives uptake
• support lowers patient friction
• payer engagement aids conversion

electroCore, Inc. uses clinical education and support to teach clinicians and patients how to place the device, set the dose, and follow the right treatment path, which matters because misuse can cut adherence and results. In fiscal 2025, the company kept building recurring use through a portable, at-home therapy model, so ongoing support is part of retention, not just onboarding.

• Train on placement and dosing
• Support real-world adherence
• Help patients stay on therapy

electroCore, Inc. relies on its commercial team and payer staff to turn clinician awareness into prescriptions. Sales, market access, and reimbursement personnel support education, account penetration, and insurance navigation, which matters because the company’s 2024 net revenue was $22.2 million and each covered win can lift repeat use.

• Drives clinician adoption
• Opens payer access
• Supports reimbursement

electroCore, Inc. is headquartered in Rockaway, New Jersey, where it was established in 2005. The site houses management, commercialization, and corporate functions, and it anchors the Company Name’s U.S.-based operations.

• Rockaway, New Jersey HQ
• Founded in 2005
• Supports management and commercialization
• Base for U.S. operations

electroCore, Inc.'s rechargeable long-life device is built for repeated use over many years, so patients replace it less often and face a simpler ownership model. That durability helps support ongoing use in chronic care, where lower hassle can improve adherence and retention.

• Rechargeable, repeat-use design
• Fewer replacements over time
• Lower-friction patient ownership
• Supports long-term care relationships

electroCore, Inc.'s prescription-only headache care keeps use under clinician oversight, so treatment fits a formal care plan for adults with migraine or episodic cluster headache. That targeting matters in a market where migraine affects about 1 in 7 people worldwide, and it supports more disciplined use than OTC self-treatment.

• Clinician-led use
• Fits care plans
• Targets migraine, cluster headache

Prescription status also helps doctors steer patients to the right dose and timing, which can improve persistence and follow-up in real care.

Recurring refill management fits electroCore, Inc. because nVNS is designed for long-term use, so follow-up drives replacements, renewals, and therapy support. That post-sale contact turns each device into an ongoing relationship, not a one-time sale.

In electroCore, Inc. filings, repeat patient engagement supports retention and service revenue around a customer base that must keep using the therapy to keep getting value.

• Replacements and renewals create repeat touchpoints
• Ongoing support helps adherence and retention
• Long-term use keeps the relationship active

Hospitals, clinics, and prescribers need account-level support and clear training, and electroCore uses field teams plus medical education to keep those relationships active. That support helps drive adoption and repeat prescribing, which matters in a model built on ongoing clinical use.

• Field teams support account adoption
• Medical education builds prescriber confidence
• Repeat prescribing sustains revenue

electroCore, Inc.'s company website is a key information and lead-generation channel, giving patients and clinicians product details, support, and access resources for its prescription gammaCore device. As a digital first touchpoint, it helps move visitors from awareness to inquiry, which matters in a market where the company reported $38.6 million in 2025 revenue.

• Shares product details and support fast
• Guides patients and clinicians to next steps
• Captures early prescription demand online

Health-system accounts are a key institutional channel for electroCore, Inc. because integrated delivery networks and large clinics can place many prescribers behind one buying decision, which helps a niche neuromodulation therapy scale faster. This channel also supports repeat use across larger patient pools, so one account can matter more than many small offices.

• One contract can reach multiple prescribers
• Large clinics can lift patient volume fast
• Best fit for niche neuromodulation scale

Neurology and pain clinics are concentrated care settings for electroCore, Inc., where patients with migraine and other pain conditions can be diagnosed, prescribed, and followed up fast. These accounts matter for repeat use and account-based selling, since one clinic can support many recurring patients and tighten therapy adherence.

electroCore, Inc. reported FY2024 net sales of $23.8 million, showing why clinic access and repeat volume matter for growth.

• Concentrated patient flow
• Faster diagnosis and prescribing
• Repeat volume from follow-up care
• Good fit for account-based selling

Integrated health systems are a key customer segment for electroCore, Inc. because they bundle prescribers and patients across one network; the U.S. has about 6,100 hospitals, so system-wide formulary, pathway, and protocol adoption can move access fast. Their scale can also lift utilization by putting one therapy into many sites of care.

• One network can reach many prescribers
• Formulary access can speed adoption
• Scale can lift use across sites

Regulatory and quality spending is a fixed drag on electroCore, Inc. because FDA compliance, document control, audits, complaint handling, and post-market surveillance never stop. For a regulated medical device business, these are non-discretionary costs that rise with product volume and regulatory scrutiny, so they stay embedded in operating expense.

• FDA compliance and quality systems are ongoing costs
• Audits, complaints, and surveillance must be maintained
• These costs are non-discretionary in medical devices

General and administrative costs cover electroCore, Inc.'s HQ work: finance, legal, HR, IT, and board oversight. As a commercial-stage public Company Name, these fixed costs must be funded while sales scale, so G&A stays a key drag on operating leverage until revenue grows faster than overhead.

• HQ overhead supports public-company duties
• Fixed costs rise before scale kicks in
• Controls, reporting, and governance matter

electroCore, Inc. can sell outside the U.S. through local distributors or regional access deals, so international channel sales add a second revenue path beyond domestic direct sales. This helps diversify the revenue base and can widen reach without building a full local sales force in every market.

• Local distributors expand market access
• Regional deals can speed entry
• Non-U.S. sales reduce concentration risk

electroCore, Inc. makes more revenue when payer coverage expands, hospitals adopt faster, and each account uses more prescriptions. In 2025, that access model mattered because reimbursement and health-system uptake drive unit volume, which is the main lever for prescription medical devices.

• More payer coverage = more script volume
• Institutional adoption lifts account penetration
• Better access supports repeat device sales